Dr. Paquette is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8700 Beverly Blvd.
AC1070
Los Angeles, CA 90095Phone+1 310-423-1160Fax+1 310-659-8045
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1990- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1984 - 1987
Ohio State University College of MedicineClass of 1984
Certifications & Licensure
CA State Medical License 1987 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia Start of enrollment: 2006 May 01
- Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome Start of enrollment: 2007 Apr 01
- Stem Cell Gene Therapy for Sickle Cell Disease Start of enrollment: 2014 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 359 citationsPonatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trialJorge E. Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp le Coutre, Ronald Paquette
Blood. 2018-07-26 - 200 citationsSomatic SETBP1 mutations in myeloid malignanciesHideki Makishima, Kenichi Yoshida, Nhu Nguyen, Bartlomiej P Przychodzen, Masashi Sanada
Nature Genetics. 2013-08-01 - 33 citationsLongitudinal SARS-CoV-2 mRNA vaccine-induced humoral immune responses in cancer patients.Jane C. Figueiredo, Noah Merin, Omid Hamid, So Yung Choi, Tucker Lemos
Cancer Research. 2021-11-10
Press Mentions
Cedars-Sinai’s Stem Cell and Bone Marrow Transplant Program Recognized with Two Major Hallmarks of QualityJanuary 18th, 2023- Hitting Stem Cell and CAR T TargetsJanuary 17th, 2023
- Blood & Marrow Transplant Outcomes Exceed ExpectationsJanuary 18th, 2022
Grant Support
- Phase I Study Of Recombinant Human Hemoglobin (Rhb1.1) In Patients W/AnemiaNational Center For Research Resources1999–2001
- Phase I/II Trial Of Recombinant Methionyl Human Stem Cell FactorNational Center For Research Resources1995–1999
- Phase I Study Of Recombinant Human Hemoglobin (Rhb1.1) In Patients W/Anemia ASSNational Center For Research Resources1998
- Myeloid Specific Regulation Of IGG FC Receptor Type INational Heart, Lung, And Blood Institute1994–1997
- Myeloid-Specific Regulation Of IGG FC Receptor Type INational Heart, Lung, And Blood Institute1993
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
